Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04733612
Other study ID # 20135
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2016
Est. completion date February 26, 2018

Study information

Verified date January 2021
Source Istanbul University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of our study was to assess awareness-raising of medication adherence (MA), physical activity (PA), fasting blood glucose (FBG), and glycated hemoglobin A (HbA1c) values by providing information on diabetes via short message (SMS) technology.


Description:

The study investigates T2DM patients who have not had surgery or cardiac event in the last 3 months, between the ages of 40 and 64 years, with T2DM diagnosis between the last 1 and 10 years and oral antidiabetic therapy for at least 1 The study design is a single-blinded randomized, controlled study, and was conducted in the Diabetes Polyclinic of the Istanbul University Medical Faculty Hospital. Patients randomly assigned to the intervention group, in addition to traditional treatment received three to four informative SMS messages per week during the 6-month period, while the control group was followed in accordance with the traditional treatment schedule.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date February 26, 2018
Est. primary completion date December 20, 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 64 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of Type 2 Diabetes Mellitus (T2DM) between the last 1 and 10 years - Being aged between 40 and 64 years old, - Is treated for a minimum of 1 year with at least one oral antidiabetic drug. Exclusion Criteria: - Clinical diagnosis of T2DM for less than 1 year or more than 10 years. - Those who have had surgery or a cardiac event in the last 3 months or during the investigation. - Those under 40 and over 64 years of age. - Patients with T2DM that have not been treated with oral antidiabetic medication. - Volunteers who once did not participate in the control examinations in both groups were excluded from the evaluation.

Study Design


Intervention

Other:
Informative messages
In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months. The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University

Outcome

Type Measure Description Time frame Safety issue
Primary Fasting blood glucose After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). Beginning
Primary Change from Baseline Fasting blood glucose at 3 months After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). 3 months after beginning
Primary Change from Baseline Fasting blood glucose at 6 months After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). 6 months after beginning
Primary Glycated hemoglobin A (HbA1c) In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method. Beginning
Primary Change from Baseline of Glycated hemoglobin A (HbA1c) at 3 months In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method 3 months after beginning
Primary Change from Baseline of Glycated hemoglobin A (HbA1c) at 6 months In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method 6 months after beginning
Primary Physical Activity level The International Physical Activity Questionnaire (IPAQ) was used to evaluate the physical activity level of the participants at the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome.
Beginning
Primary Change from Baseline Physical Activity at 3 months The International Physical Activity Questionnaire (IPAQ) was used to evaluate the physical activity level of the participants at at 3 months after the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome.
3 months from beginning
Primary Change from Baseline Physical Activity at 6 months The International Physical Activity Questionnaire (IPAQ) was used to evaluate the change in physical activity level of the participants at at 6 months after the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome.
6 months from beginning
Primary Drug Adherence The Morisky Medication Adherence Scale (MMAS-8) was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence.
Beginning
Primary Change from Baseline Drug Adherence at 3 months The Morisky Medication Adherence Scale was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence.
3 months after beginning
Primary Change from Baseline Drug Adherence at 6 months The Morisky Medication Adherence Scale (MMAS-8) was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence.
6 months after beginning
Primary Quality of Life Assessed by SF-36v2 The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. Beginning
Primary Change from Baseline Quality of Life Assessed by SF-36v2 at 3 months The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. 3 months after beginning
Primary Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. 6 months after beginning
Secondary Baseline blood pressure The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. Beginning
Secondary Change from Baseline blood pressure at 3 months The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. 3 months after beginning
Secondary Change from Baseline blood pressure at 6 months The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. 6 months after beginning
Secondary Baseline heart rate The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. Beginning
Secondary Change from Baseline heart rate at 3 months The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. 3 Months After Beginning
Secondary Change from Baseline heart rate at 6 months The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. 6 Months After Beginning
Secondary Baseline Body Mass Index The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula:
BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square.
Beginning
Secondary Change from Baseline Body Mass Index at 3 months The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula:
BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square.
3 months after Beginning
Secondary Change from Baseline Body Mass Index at 6 months The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula:
BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square.
6 months after Beginning
Secondary Baseline body fat ratios The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. Beginning
Secondary Change from Baseline Body Fat Ratios at 3 Months The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. 3 Months After Beginning
Secondary Change from Baseline Body Fat Ratios at 6 Months The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. 6 Months After Beginning
Secondary Baseline waist/hip ratio The volunteers waist and hip circumference and waist/hip ratio were measured by tape measure after 8 hours of fasting in the morning with thin clothes on them.
Waist circumference (cm) was measured at the level of the umbilicus and hip circumference (cm) at the level of the femur trochanter major.
Waist/hip ratio (WHR) were were calculated as follows
waist/hip ratio= waist circumference / hip circumference
Beginning
Secondary Change from Baseline waist/hip ratio at 3 Months The volunteers waist and hip circumference and waist/hip ratio were measured by tape measure after 8 hours of fasting in the morning with thin clothes on them.
Waist circumference (cm) was measured at the level of the umbilicus and hip circumference (cm) at the level of the femur trochanter major.
Waist/hip ratio (WHR) were were calculated as follows
waist/hip ratio= waist circumference / hip circumference
3 Months after Beginning
Secondary Baseline Diet and Nutritional Habits The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. Beginning
Secondary Change from Baseline Diet and Nutritional Habits at 3 months The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. 3 Months after Beginning
Secondary Change from Baseline Diet and Nutritional Habits at 6 months The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. 6 Months after Beginning
Secondary Baseline Energy Intake From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. Beginning
Secondary Change from Baseline Energy Intake at 3 months From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. 3 months after Beginning
Secondary Change from Baseline Energy Intake at 6 months From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. 6 months after Beginning
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A